← Human Trials & Peer-Reviewed Studies

Noninvasive high-intensity focused ultrasound for skin brightening efficacy using a topical agent containing glutathione and hyaluronic acid

Plain-language guide to PMID 39326871 (2024): controlled clinical trial study of Glutathione in 20 volunteers.

Key Facts

PMID
39326871
Journal
The Journal of dermatological treatment
Year
2024
Study type
Controlled Clinical Trial
Authors
Yi KH et al. (9 authors)
DOI
10.1080/09546634.2024.2406932

What This Study Did, in Plain Language

What Was Tested

Researchers studied Glutathione in this controlled clinical trial publication.

To evaluate clinical and photographic outcomes of HIFU combined with a topical agent versus the topical agent alone.

Why It Was Studied

High-intensity focused ultrasound (HIFU) is well-documented for skin rejuvenation, lifting, and tightening.

However, its synergistic effects with topical agents, enhanced by HIFU-induced vibration and heat, remain underexplored.

Who Took Part

According to the abstract, 20 volunteers were involved.

The age groups tagged for this paper are adults and middle-aged adults, women only.

This non-randomized controlled trial involved 20 female volunteers (ages 30-55) divided into two groups.

Outcomes were assessed using digital photography, patient satisfaction surveys, and the A-One Smart™ system for fine wrinkles, hyperpigmentation, and hydration.

How the Study Was Run

Group A (n = 10) received two HIFU sessions combined with a topical agent containing glutathione and hyaluronic acid.

Group B (n = 10) received the topical agent alone.

What Was Measured

Topics PubMed links to this paper include Hyaluronic Acid, Skin Aging, Patient Satisfaction, Glutathione, Cosmetic Techniques, Rejuvenation and Combined Modality Therapy.

The authors tagged it with the keywords facial rejuvenation, high-intensity focused ultrasound (HIFU) and skin brightening.

What This Means in Plain Language

This is a controlled clinical trial of Glutathione in 20 volunteers.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The abstract goes on to report its results in about 4 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2024 (The Journal of dermatological treatment), a journal based in England.

More context: the Glutathione compound page, all human trials.

Our Notes on the Compound

Glutathione: The body's main antioxidant.

Related Pages

Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.